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ABSTRACT

Author: Valentino, Stephen, A. MS
Institution: Purdue University
Degree Received: May 2018
Title: Engineering Genetically Encoded Sensors to Study Purinergic Signaling
Committee Chair: Dr. Mathew Tantama

Extracellular adenosine triphosphate (ATP) is a key purinergic signal that mediates cell-to cell
communication both within and between organ systems. We address the need for a robust and
minimally invasive approach to measuring extracellular ATP by re-engineering the ATeam ATP
sensor to be expressed on the cell surface. Using this approach, we image real-time changes in
extracellular ATP levels with a sensor that is fully genetically-encoded and does not require an
exogenous substrate. Using live-cell microscopy, we characterize sensor performance when
expressed on cultured Neuro2A cells, and we measure both stimulated release of ATP and its
clearance by ectonucleotidases. In addition, we increase the affinity of ATeam threefold by
mutating the hinge region (R103A/R115A) of the epsilon subunit. Thus, this proof-of-principle
demonstrates a sensor to report extracellular ATP dynamics that may be useful for studying
purinergic signaling in living specimens.
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IMAGING EXTRACELLULAR ATP WITH A
GENETICALLY-ENCODED, RATIOMETRIC FLUORESCENT
SENSOR

1.1

Introduction
This chapter is a published paper with the same name, published in PLOS one, of which I

am second author.94 Extracellular adenosine triphosphate (ATP) is a central component of
purinergic signaling, and purinergic signaling contributes to a vast array of fundamental
physiological processes and pathophysiological conditions including neuron-glia communication13

, immune responses4,5, inflammation6,7, and cancer8-10. ATP is released from cells into the

extracellular space by a variety of mechanisms such as stimulated exocytosis and conductive
passage through hemichannels11-14. Following release, extracellular ATP directly modulates
purinergic receptors in an autocrine and paracrine manner15. For example, in an immune context
ATP leakage from apoptotic cells in healthy tissue13,16 or from damaged cells in injured tissue17-19
acts as a chemotactic signal for clearance by phagocytes. In the context of nervous tissue, ATP
released by astrocytes20 can regulate synaptic and network excitability21-25. Furthermore,
extracellular ATP is central to purinergic signaling not only because of its direct effects but also
because extracellular ectonucleotidases, such as CD3910 and CD7326, hydrolyze it to the additional
purinergic signaling molecules ADP, AMP, and adenosine27. Depending on the physiological
context28,29, these metabolites uniquely modulate distinct sets of ATP-gated ionotropic P2X
receptors, ATP and ADP-modulated metabotropic P2Y receptors, and P1 adenosine receptors30-32.
It is important to understand extracellular ATP dynamics as a fundamental aspect of physiology
and because ATP-dependent receptors, as well as the ATP release and clearance machinery, are
potential therapeutic targets33,34. However, deficiencies in our understanding of the broad
concentration ranges, timescales, and distances over which extracellular ATP acts currently
obscures the roles of purinergic signaling in both healthy and diseased tissue. Therefore, in order
to establish a clear picture of purinergic signaling in physiology, it is necessary to distinguish the
role of extracellular ATP from its hydrolysis products and to quantitatively measure extracellular
ATP dynamics directly.
Direct measurements of extracellular ATP employ diverse techniques including
biochemical endpoint assays, microelectrode sensors, and fluorescent ATP analogues15,35. In
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particular, membrane-tethered luciferase continues to provide critical new knowledge about
purinergic signaling in cancer biology, immunology, and beyond36-42. These methods have yielded
invaluable insight into ATP signaling; however, new methods are needed to push beyond the
current limitations in spatial and temporal resolution. These limitations prevent the precise
understanding of changes in extracellular ATP levels that occur within seconds and minutes at
cellular and subcellular length scales. For example, current techniques are limited in their
applications to complex tissue because they require chemical additives, damage tissue with an
invasive probe, or consume ATP upon measurement. More recently, genetically-encoded
fluorescent protein-based sensors have been developed as relatively non-invasive tools with high
spatiotemporal resolution to study intracellular ATP. These include the ATeam family of sensors
that report intracellular ATP dynamics by a change in Förster resonance energy transfer (FRET)
between two fluorescent proteins43, and the QUEEN44 and Perceval45,46 sensors that use a single
circularly-permuted fluorescent protein. Though exploited in a number of intracellular contexts,
these sensors have not been used to detect extracellular ATP.
Here, we re-engineer a ratiometric ATeam FRET-based ATP sensor by targeting it to the
cell surface, and report its use as a genetically-encoded fluorescent sensor of extracellular ATP.
We report its design, characterization, and proof-of-principle that it can be used to image and
monitor real-time changes in extracellular ATP levels caused by endogenous clearance and release
mechanisms in cell culture, using Neuro2A cells as a principal test platform for the sensor.

1.2

1.2.1

Results

Sensor Construction and Characterization
To generate a sensor of extracellular ATP, we targeted a soluble ATeam ATP sensor to the

cell surface. The ATeam family of sensors, first developed by Imamura and co-workers, are
generally composed of an ε subunit from a bacterial FOF1-ATP synthase that is fused between a
cyan fluorescent protein (CFP) and a yellow fluorescent protein (YFP)43. ATP binding induces a
conformational change that increases Förster-type resonance energy transfer (FRET) between the
CFP donor and YFP acceptor43. The soluble ATeam3.10 sensor was chosen as a starting point
because it can provide a ratiometric fluorescence readout, which facilitates quantitative and
longitudinal live-cell imaging studies by normalizing for expression level and decreasing signal
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drift. It is also a higher-affinity variant that better matches the estimated physiological range of
extracellular ATP. In order to target the soluble ATeam3.10 sensor to the cell surface, we
employed a strategy previously used to engineer extracellular glutamate sensors47-49. The
ATeam3.10 sensor was fused between an IgΚ leader sequence50 on the N-terminus and a
transmembrane anchor domain from the platelet-derived growth factor receptor (PDGFR)51 on the
C-terminus. These modifications direct the sensor to the secretory pathway and tether the sensor
to the extracellular face of the plasma membrane, respectively (Fig 1). The resulting membranetethered sensor was termed ecAT3.10 (extracellular ATeam3.10).
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Figure 1.1. The ecATeam3.10 sensor detects extracellular ATP.
(A) Schematic of ecAT3.10 design in which the ATeam3.10 FRET-based ATP sensor is displayed
on the cell surface via a PDGFR transmembrane anchor. (B) Fluorescence intensity in the FRET
channel increases upon wash-in of 100 µM ATP while the CFP donor intensity decreases. As
expected, the YFP direct acceptor channel does not show an ATP-dependent change. Cells were
imaged under continuous perfusion. (C) Representative widefield fluorescence images for the cells
analyzed in (D-E). The first panel in the YFP channel shows morphology, the subsequent panels
are false colored to show the change in the normalized FRET/CFP pixel-by-pixel ratio signal.
Scale bar is 20µm. (D) The average FRET/CFP emission ratio, which we refer to as the ratio signal,
shows a robust increase of 0.27 ± 0.01 (n=41 cells). Values and solid line traces are cell means,
and errors and error bars are standard errors of the means. (E) To account for drift, a linear baseline
was fitted, and the ratio signal was normalized on a cell-by-cell basis (individual cells, gray),
showing an average fold change of 1.127 ± 0.005 (population average, red).

Initially, the ecAT3.10 sensor was expressed in cultured mammalian cells to test for
expression at the cell surface and for a response to exogenous ATP. Even in widefield imaging
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mode, the fluorescence signals were clearly localized to the cell perimeter of Neuro2A cells,
indicating successful targeting of ecAT3.10 to the plasma membrane (Fig 1). Furthermore, under
continuous bath perfusion conditions, wash-in of 100 µM ATP resulted in an increase in FRET
emission intensity and a decrease in CFP donor fluorescence intensity, which is consistent with
the expected increase in FRET upon ATP binding (Fig 1; S1 Fig). At the cell population level, the
ecAT3.10 FRET/CFP emission ratio signal (referred to as the “ratio signal”) reached a maximal
increase of 0.27 ± 0.01 (Fig 1), representing a peak fold-increase of 1.127 ± 0.005 (mean ± sem,
n=41 cells) in the presence of ATP relative to the ratio signal in the absence of ATP (Fig 1D).
Upon washout of extracellular ATP from the bath, the ecAT3.10 ratio signal returned to baseline,
demonstrating that the sensor can be used to reversibly detect changes in extracellular ATP.
Interestingly, ecAT3.10 was able to detect significant cell-to-cell variability in the response
magnitude (Fig 1E), which may be related to physical characteristics of the cell surface or
endogenous activity under these slow-perfusion conditions in the absence of inhibitors52. It is
important to note that the variability is not caused by differences in sensor expression levels
because the ratio signal is independent of the concentration of the sensor (S1 Fig).
After demonstrating the reversibility of the sensor, we examined the spatial profile of the
ecAT3.10 response in greater detail to show that ecAT3.10 is a faithful reporter of extracellular
ATP. The sensor exhibited strong surface-targeted fluorescence signals, but intracellular punctate
fluorescence was also apparent (Fig 1; Fig. 2). Intracellular punctae have been observed during
overexpression of fluorescent protein sensors by other groups, and it is attributed to excess protein
resident in the endoplasmic reticulum47. Sensor responses were therefore analyzed for ratio signal
changes within subcellular ROIs including the cell membrane and intracellular regions of interest
using confocal microscopy. The confocal analysis confirmed that the fluorescence response
originates exclusively from the membrane (Fig. 2). Furthermore, even in widefield imaging mode
the whole-cell fluorescence signal response is reflective of the membrane response (S2 Fig.). Thus,
ecAT3.10 can be conveniently used with either confocal or widefield microscopy, and the
subsequent experiments presented here utilized widefield microscopy.
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Figure 1.2. Surface-localized ecAT3.10 responds to the addition of extracellular ATP.
High magnification confocal microscopy demonstrates that the ecAT3.10 ratio signal response to
extracellular ATP occurs exclusively at the membrane. (A) Representative confocal fluorescence
intensity images in the CFP and FRET channels show strong membrane localized signal and some
intracellular puncta. Scale bar is 20 µm. (B) Pixel-by-pixel FRET/CFP ratio images before (left)
and after addition of 100 µM ATP (right) illustrates a response at the membrane only. (C-E) Line
profile analysis for the two example cells shown in (A). A 5-pixel width line region of interest was
drawn through the membrane and peak areas of intracellular fluorescence. (C) The fluorescence
intensity line profiles exhibit peaks at the membrane and also from intracellular locations that are
likely ER/Golgi in origin. The line profiles from the ratio images shown in (B) before (D) and after
(E) the addition of extracellular ATP clearly show that the ecAT3.10 ratio signal increases at the
membrane and not from the intracellular sites. (F) After 3 minutes, 100 µM ATP was added. The
time course shows that the membrane-localized ratio signals increase, but the signals from
intracellular regions do not change (mean ± sem for three experiments with n=32 cells, n=60 cells,
and n=46 cells).
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After our initial tests, we characterized the concentration range in which ecAT3.10 can
detect extracellular ATP. Live Neuro2A cells expressing ecAT3.10 were imaged at room
temperature with continuous bath perfusion to minimize cell-to-cell variability. Increasing
concentrations of exogenous ATP from 0 µM to 1000 μM were washed onto the cells during realtime image acquisition, and steady-state was achieved before changing the extracellular ATP
concentration (Fig 3). The sensor “on-cell” responses exhibited concentration-dependent increases
of the ecAT3.10 ratio signal, and an apparent affinity equilibrium constant, Kapp of 12 ± 5 µM
(mean ± sem, n = 4 experiments), was determined when data were fitted with a Hill equation (Fig
3). Importantly, the apparent affinity of ATP for the purified soluble ATeam3.10 sensor was
approximately 20-fold higher (Kapp = 0.52 ± 0.02 μM, mean ± sem, n=14 experiments) (Fig 4)
compared to the “on-cell” response (Fig 3). Taken together, the difference between the Kapp
values for ATP between ecAT3.10 expressed on living cells and purified AT3.10 in vitro may
reflect changes in the binding properties for ecAT3.10 imparted by surface-tethering of the sensor.
There has been concern in the literature that glycosylation of ATeam can inactivate and alter the
sensor’s properties53,54, but similar to other studies55 we did not find evidence that glycosylation
affects sensor function (S3 Fig.). Despite the change in affinity, the sensitivity range overlapped
with the reported physiological range of extracellular ATP from basal nanomolar to peak
micromolar concentrations56,57.
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Figure 1.3. Characterization of ATP affinity and response kinetics.
ecATeam3.10 exhibits a concentration-dependent change in FRET/CFP ratio signal. Live
Neuro2A cells expressing ecAT3.10 were imaged at room temperature under continuous perfusion,
during which increasing concentrations of extracellular ATP were washed in a stepwise fashion.
(A) A representative time course from one experiment with four cells. Each grey trace represents
the response from an individual cell in which the regions of interest were drawn around the
membrane. The orange trace is the mean response. (B) Summary of ATP dose-response data from
five independent experiments, each represented its own symbols. The orange squares represent
data from (A), and the dashed red curve is fit to the mean of all experiments. In four of the five
experiments, sufficient data was available for independent fitting to a Hill equation (mean ± sem,
n=4 experiments: K = 12 ± 5 µM, Ratiomax/Ratiomin = 1.23 ± 0.01, n = 1.4 ± 0.2). A global fit
of data from all five experiments was also performed for comparison. (fitting mean ± sem, n=5
experiments: K = 11 ± 2 µM, Ratiomax/Ratiomin = 1.28 ± 0.01, n = 0.9 ± 0.1). (C-D) ecAT3.10
responds to an increase in extracellular ATP within seconds. (C) Cells were imaged during fast
perfusion wash in of 100 µM ATP, and the sensor exhibited an increase in FRET within seconds
(n = 27 cells, 3 experiments; twoAn expanded view of the initial response shown in (C). Red, FRET fluorescence channel intensity.
Yellow, YFP fluorescence channel intensity. Dotted black curve, two-exponential fit.
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Figure 1.4. ecATeam3.10 detects ATP hydrolysis by ectonucleotidases.
Live Neuro2A cells expressing ecAT3.10 were imaged under non-perfusion, static bath conditions.
(A) The addition of 10 µM ATP did not elicit a response (black) unless the cells were pre-treated
with the ectonucleotidase inhibitor ARL67156 at 100 µM (red). Apyrase addition degrades
extracellular ATP confirming a reversible ATP-specific sensor response. (B) Ectonucleotidase
inhibition by ARL67156 pre-treatment also potentiated responses when 30 µM ATP was added.
Vehicle, black. ARL67156, red. (A) and (B), n=6, 2 independent investigators. (C) ARL67156
does not directly affect the ATeam3.10 sensor response to ATP.
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We also characterized the kinetics with which the ecAT3.10 sensor responds to
extracellular ATP. Neuro2A cells expressing ecAT3.10 were imaged at room temperature with
continuous perfusion at a rate of 5 mL/min in a laminar flow fast perfusion chamber. In order to
increase the acquisition speed, only the FRET and YFP fluorescence intensity channels were
collected at 2 second intervals, which did not require any filter changes. The ecAT3.10 sensor
responded within several seconds upon wash in of 100 µM ATP, and on average the response was
best fit to a two exponential function with a fast time constant, τ = 13 ± 1 sec, and a slow time
constant, τ = 172 ± 18 sec (n=27 cells, 3 experiments) (Fig 3; S4 Fig). Thus, the sensor can detect
micromolar changes in extracellular ATP concentrations within seconds.

1.2.2

ecAT3.10 Reports Extracellular ATP Turnover by Ectonucleotidase Activity
We next demonstrated that ecAT3.10 can be used to detect the clearance of extracellular

ATP via ectonucleotidase activity in cell cultures. During the measurement of the ATP affinity of
ecAT3.10, continuous bath perfusion conditions were employed in order to continuously replenish
ATP and control the extracellular ATP concentration.

Physiologically, however,

ectonucleotidases contribute to purinergic signaling dynamics by clearing extracellular ATP by
hydrolysis27,58, thereby generating ADP, AMP, and adenosine, which can act independently as
purinergic signals. In order to test ecAT3.10’s ability to detect endogenous ectonucleotidase
activity58, we performed experiments in which a single addition of exogenous ATP was made to
cultured Neuro2A cells expressing ecAT3.10 in an imaging dish under static bath conditions
without solution exchange. We initially used Neuro2A cells because they express the
ectonucleotidase NTPDase1 (CD39)51.
Our observations indicate that endogenous ectonucleotidases exhibit substantial activity to
maintain low basal extracellular ATP levels around cultured cells. We first tested the addition of
10 μM ATP to ecAT3.10-expressing Neuro2A cells under static bath conditions. The concentration
was chosen to mimic moderate to high physiological concentrations and because it demonstrated
approximately half-maximal responses in the continuous perfusion experiments (Fig 3).
Surprisingly, under static bath conditions no significant increase in the sensor ratio signal was
detected (Fig 4), which is in stark contrast to bath perfusion experiments (Fig 3). However, pretreatment with the ectonucleotidase inhibitor ARL6715659 reconstituted the average peak response
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(vehicle, 1.02 ± 0.01 versus 100 µM ARL67156, 1.10 ± 0.02, mean ± sem, n=6 experiments from
2 independent investigators, p=0.009, t-test), and therefore the loss of signal change in the absence
of ARL67156 is not caused by a loss of responsivity of the sensor itself. Potentiation of the
response by ARL67156 indicates that high ectonucleotidase activity turns over extracellular ATP
at a significant rate, at least at the cell surface. Importantly, 100 µM ARL67156 had no effect on
the ability of purified soluble ATeam3.10 to detect ATP in vitro. The dose-response and Kapp
values for ATP in the presence and absence of ARL67156 were not significantly different (0.52 ±
0.02 μM, n=14 versus 0.46 ± 0.07 μM, n=5, p=0.34, t-test) (Fig 4). Furthermore, the sensor ratio
signal remained elevated until exogenous apyrase (3U/mL, high ATPase activity) was added to
degrade the ATP (Fig 4). Apyrase itself does not affect the ability of ecAT3.10 to detect ATP (S5
Fig), and the decrease is not due to loss of sensor by internalization because the membranelocalized ratio signal is insensitive to sensor concentration. The apyrase addition caused a decrease
in ecAT3.10 signal, demonstrating that the sensor remained responsive and was specific to ATP
(Fig 4).
We next tested whether ectonucleotidase activity could clear surface ATP levels after the
addition of a higher bulk concentration of extracellular ATP. Upon addition of 30 μM ATP, an
initial increase in the sensor ratio signal was detected, and vehicle addition did not elicit a response
(Fig 4; S5 Fig). However, the sensor response to ATP was transient. After reaching a peak, within
minutes the ecAT3.10 ratio signal spontaneously decreased, which is consistent with the hydrolytic
breakdown of ATP by endogenous ectonucleotidase activity (Fig 4). Pretreatment with the
ectonucleotidase inhibitor ARL67156 abrogated the spontaneous decrease and potentiated the
peak response (vehicle, 1.07 ± 0.02 versus 100 µM ARL67156, 1.14 ± 0.02, mean ± sem, n=6
experiments from 2 independent investigators, p=0.02, t-test). The effect of ARL67156 supports
the hypothesis that endogenous ectonucleotidases actively clear extracellular ATP, though
hydrolytic activity was not able to completely suppress an increase in cell surface ATP when
challenged with larger bulk ATP increases. In addition, the time-course of the response is complex
under these static bath conditions because diffusion rate, clearance rate, and endogenous release
(discussed below) rate all contribute to the overall dynamics. Overall, these data demonstrate that
ecAT3.10 can be used to image and measure extracellular ATP clearance by endogenous
ectonucleotidase activity on live cultured cells.
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1.2.3

ecAT3.10 Detects Nucleotide-stimulated Endogenous ATP Release
We next demonstrated that ecAT3.10 can be used to measure nucleotide-stimulated release

of endogenous ATP from cells. It has previously been reported that P2X7 receptors can mediate
ATP release from Neuro2A cells60, and it is well established that ATP61-65 and ADP66,67 can
stimulate the release of ATP from a variety of cultured cells. The ATeam sensor itself can detect
changes in ATP within seconds43, which is well-matched to detect nucleotide-stimulated ATP
release. Nucleotide-stimulated ATP release has previously been reported to cause an initial
increase in extracellular ATP within seconds that can continue to increase and remain elevated
over minutes60-67, and in particular ATP-stimulated ATP release under static bath conditions has
been observed to increase over tens of minutes62.
Here, we imaged ecAT3.10-expressing Neuro2A cells under static bath conditions in order
to observe persistent increases in extracellular ATP. In these experiments, technical replicates were
imaged in a multi-well plate at 5 minute intervals. We observed a pronounced biphasic response
following the addition of 100 μM ATP to ecAT3.10-expressing in Neuro2A cells (Fig 5) or
HEK293 cells (S6 Fig). On average, a secondary increase in the ecAT3.10 ratio signal followed
the initial decrease that we attribute to ARL67156-sensitive ectonucleotidase activity. This
observation led to the hypothesis that the secondary increase is caused by a purinergic receptormediated release of intracellular ATP from cells. For example, such a release could plausibly be
stimulated by ATP itself60, one of its hydrolysis products, or possibly an intermediary purinergic
ligand released by the initial ATP stimulation68-73. Therefore, we tested exogenous addition of
ADP, adenosine, UDP, and UTP in comparison to ATP, each at a bulk extracellular concentration
of 100 μM. The addition of ADP caused a robust increase in the ratio signal that was further
potentiated by pretreatment with ARL67156 (Fig 5), whereas adenosine, UDP, and UTP did not
elicit any response (S6 Fig). Clearly, there are complex differences between the ATP-elicited and
ADP-elicited dynamics that likely reflect a number of signaling events that are well beyond the
scope of this study. We therefore focused our study of the nature of the ADP-stimulated response
to determine if the response is caused directly by ADP binding to the sensor or if ADP stimulates
an endogenous release of intracellular ATP.
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Figure 1.5. ecAT3.10 detects nucleotide-stimulated release of ATP from cells.
(A) A biphasic response was apparent on average when 100 µM ATP was added at time = 30
minutes to the static bath of ecAT3.10-expressing Neuro2A cells. The decrease in signal at time =
45 minutes is due to ARL67156-sensitive ectonucleotidase activity, and the subsequent increase
in signal after time =55 minutes reports a secondary release of endogenous ATP from cells. (B)
Pretreatment with 100 µM ARL67156 abrogates the transient decrease in ectonucleotidase activity.
(C) Addition of 100 µM ADP also stimulate a release of ATP from cells, which was potentiated
by pretreatment with ARL67156 (D). Apyrase addition degrades extracellular ATP confirming a
reversible ATP-specific sensor response. Solid lines show average responses from ecAT3.10, and
dashed traces show average responses from the negative control ecATYEMK sensor (n=3).

Our subsequent experiments indicate that the ecAT3.10 response is specific to ATP and
not caused by an effect of ADP directly on the sensor. First, as a low affinity ligand for the soluble
ATeam3.10 sensor, ADP could directly bind the sensor to produce an increase in the ratio signal.
In fact, 100 μM ADP nearly saturates the purified soluble ATeam3.10 sensor, which suggests that
ADP binding to ecAT3.10 could be responsible for the observed live-cell response from ecAT3.10expressing Neuro2A cells43. However, the ATeam3.10 sensor is nearly 100-fold more selective
for ATP compared to ADP (S7 Fig.), and given our observation that the ATP response profile of
surface-bound ecAT3.10 is drastically shifted relative to soluble ATeam3.10, we tested the
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response of ecAT3.10 to direct ADP binding with bath perfusion experiments (Fig 6). In contrast
to the soluble sensor, ecAT3.10 showed a minimal fold increase in ratio signal upon wash-in of
ADP (30 μM ADP, 1.009 ± 0.002; 100 μM ADP, 1.026 ± 1.005) compared to a subsequent washout of ADP and wash-in of ATP (30 μM ATP, 1.106 ± 0.009; 100 μM ATP, 1.14 ± 0.01, mean ±
sem, n=3 experiments). Although the ecAT3.10 is not perfectly specific for ATP compared to ADP,
it may be improved with future engineering. However, the current sensor is 5-10 times more
responsive to ATP, and thus, while a direct response to ADP binding may contribute a minor
fraction of the signal, it does not account for the total magnitude of the response, supporting a
stimulated release of ATP. Interestingly, these data are consistent with the approximate 20-fold
affinity difference observed for ATP between ecAT3.10 and soluble ATeam3.10 (Fig 3). Second,
we showed that the ADP-mediated increase in the sensor ratio signal was not due to a direct effect
of the nucleotides on the individual fluorescent proteins in ecAT3.10. To test this we used a low
affinity ATeam variant, ATeam1.03YEMK43, to generate the surface-targeted sensor,
ecATYEMK. In contrast to ecAT3.10, this negative control construct ecATYEMK showed no
response to either ATP or ADP (Fig 5), confirming that the response is not a non-specific effect
on the individual CFP or YFP. Taken together, these data show that the increase in ecAT3.10 ratio
signal cannot be solely attributed to direct ADP binding to the sensor, and they suggest that the
increase is cause by an ADP-stimulated release of cellular ATP.
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Figure 1.6. ecATeam3.10 detects ADP-stimulated release of endogenous ATP from live Neuro2A
cells.
(A) ecAT3.10-expressing Neuro2A cells were imaged under continuous perfusion conditions to
demonstrate that ecAT3.10 has greater sensitivity to ATP compared to ADP. (B) Under static bath
conditions, paired measurements by ecAT3.10 real-time imaging and endpoint luciferase assays
demonstrate that ADP stimulates ATP release. In (A) and (B) grey traces are individual cells, and
the bold trace is the cell mean. Arrows in (B) and (C) indicate the addition of ADP and apyrase,
sequentially. In (C), time points represent samples from the bath solution taken during the
ecAT3.10 imaging experiment shown in (B).
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To confirm that the ecAT3.10 response is measuring an ADP-stimulated release of ATP
from the Neuro2A cells, we measured extracellular ATP levels with an orthogonal biochemical
assay, the widely-accepted luciferase end-point assay. To carry out this experiment, cells were
stimulated with 100 μM ADP and the real-time ecAT3.10 response was measured by fluorescence
microscopy (Fig 6). Simultaneously during imaging, samples of the static bath solution were taken
at intervals, and the extracellular ATP levels were determined with a commercial luciferase-based
ATP detection kit (Fig 6). As expected, the addition of ADP caused an increase in the extracellular
ATP concentration that, as measured by the luciferase detection method, grossly mirrored the
temporal pattern of the ecAT3.10 signal. Specifically, both the real-time ecAT3.10 ratio signal
and the end-point luciferase measurements increased following the addition of ADP, and both
decreased following the addition of apyrase (n = 4 experiments) (Fig 6; S7 Fig). We did observe
differences in the detailed changes in extracellular concentration detected by ecAT3.10 versus the
luciferase measurements, which reflect the differences between cell surface and bulk volume
measurements57,74. These observations confirm that ecAT3.10 can detect the ADP-stimulated
release of endogenous ATP from Neuro2A cells.
ADP-stimulated accumulation of extracellular ATP may be mediated by purinergic
receptor signaling pathways, as several P2Y receptor isoforms are known to be modulated by
ADP30. Therefore, a non-specific purinergic receptor antagonist, suramin, was tested for its effects
on the ADP-stimulated release of ATP from Neuro2A cells3,30,32,75. Specifically, the ecAT3.10
response to ADP (30 µM) treatment was measured for Neuro2A cells that were pretreated with
suramin (3.3 µM), either in the presence or absence of the ectonucleotidase inhibitor, ARL67156
(100 µM) (Fig 7). Consistent with ligand-stimulated ATP release from Neuro2A cells,
pretreatment with ARL67156 potentiated the response to ADP which was reversed with
subsequent apyrase treatment as expected (Fig 7). Furthermore, the ARL67156-potentiated
ecAT3.10 response to ADP treatment was attenuated by suramin, suggesting that the ADPstimulated release of ATP into the extracellular space was mediated by purinergic receptor
signaling components (Fig 7). Suramin non-specifically targets P2X and P2Y receptors, therefore
we tested the P2Y inhibitor, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS).
Suramin and PPADS attenuated release; however, we discovered that PPADS directly altered the
sensor response (Fig S8). Despite this, the confluence of evidence described above indicates that
treatment of Neuro2A cells with ADP ultimately caused an accumulation of extracellular ATP that
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was detected by ecAT3.10, providing a proof-of-concept validation that ecAT3.10 was able to
detect cell-mediated extracellular ATP dynamics.

Figure 1.7. ADP-stimulated release of ATP release from Neuro2A cells may be mediated in part
by purinergic pathways.
(A) Average time course of ecAT3.10 ratio signal (baseline normalized, n=6 experiments) from
Neuro2A cells that were imaged under static bath conditions. 30 µM ADP was added to stimulate
release of ATP. Pretreatment with 100 µM ARL67156 (red) potentiated the response in
comparison to vehicle treatment (black). Treatment with 3.3 µM suramin (green) attenuated
extracellular ATP levels compared to vehicle (black), and treatment with suramin in the presence
of ARL67156 (blue) attenuated the release of ATP compared to ARL67156 alone (red). Apyrase
addition degrades extracellular ATP confirming a reversible ATP-specific sensor response. (B)
Summary of cell averaged peak responses for individual experiments . Peak responses: vehicle,
1.06 ± 0.01; ARL67156, 1.13 ± 0.01; suramin, 1.027 ± 0.002; ARL67156 plus suramin, 1.048 ±
0.006, mean ± sem. t-test, *p=0.004, **p=0.02, ***p=0.0004. n=6, 2 independent investigators.

1.3

Discussion
We have demonstrated that ecAT3.10 can be used to image and measure extracellular ATP

dynamics in real-time, which is a significant advance because it provides a new tool to study
purinergic signaling in live specimens. Extracellular ATP has been previously measured by a
number of end-point biochemical and biophysical assays3,15,21,61-63,76-78. Real-time monitoring of
purinergic signaling has also been achieved using ATP sniffer cells79-81, enzyme-coupled optical
fibers and electrodes21,25, and cell surface-tethered luciferase74. These methods have estimated
that basal ATP levels in cell culture and in tissue are as low as nanomolar concentrations, whereas
peak release levels have been estimated to reach micromolar concentrations, representing a
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concentration range spanning several orders of magnitude3,21,63,76-78. Real-time measurements,
including calibrated measurements from surface-tethered luciferase, are in agreement, though
these measurements may have potentially underestimated surface ATP concentrations when not
directly sampling at the cell surface76,78,82,83. Surface-tethered luciferase could also underestimate
surface levels because it requires access of a diffusible luciferin substrate and typically requires
long integration times. To overcome this, a small organic fluorescent probe84 has been used to
monitor surface ATP levels in real-time on immune cells76,78, but it requires application of a
lipidated probe. Overall, these methods variously suffer from limitations due to spatiotemporal
resolution, specificity, exogenous substrate access, or sample destruction, which limit their use in
live specimens35. A genetically-encoded sensor, such as ecAT3.10, offers the capability to
quantitatively visualize purinergic signaling with minimal perturbation after gene transfer. To this
end, we have demonstrated that ecAT3.10 is able to reversibly report changes in extracellular ATP
in a physiologically relevant concentration range.
Physiologically, clearance of extracellular ATP is constitutive, and we demonstrated that
ecAT3.10 can detect ARL67156-sensitive ectonucleotidase activity that serves to maintain a low
surface ATP concentration on cultured cells. It is therefore important to take these biological
activities into account when deciphering the sensor responses. We measured the concentrationresponse relationship between ATP and ecAT3.10 under continuous perfusion conditions to
maximally hold the bulk ATP concentration constant. However, the cell surface is likely a
privileged compartment82,83 where the observed ATP diffusion coefficient may be different from
the bulk diffusion coefficient, and both biological clearance and release contribute to the net
response57,63,76-78. For example, Neuro2A cells are known to express the ectonucleotidase CD3951,
but ecAT3.10 was able to reveal population heterogeneity at the level of single-cell analysis, which
may be caused by cell-to-cell variation in CD39 activity that dampens the response magnitude. It
is also possible that ectonucleotidase turnover of local surface ATP generates an ATP
concentration gradient that increases into the bulk bath volume, which serves as a reservoir of
diffusing ATP – though future experiments, beyond the scope of this study, are needed to test this
compartmentation explicitly. Importantly, despite the variability in the response magnitude, the
sensitivity of the sensor to ATP was consistent, supporting that ecAT3.10 reports physiological
ATP dynamics. Overall, ecAT3.10 was able to detect clearance of extracellular ATP, suggesting
that ecAT3.10 may prove useful in quantitatively characterizing CD39 activity, for example, that
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is linked to immunogenicity of various cancer cell types10. Furthermore, the high ectonucleotidase
activity that we observed in cultured cells matches well with the physiological need to prevent
non-specific activation of purinergic receptors.
To this end, we also provided evidence that ecAT3.10 could detect a purinergic receptormediated endogenous release of ATP as a proof-of-principle. It has been previously reported that
Neuro2A cells express purinergic receptors68-73 and can be stimulated to release ATP60. While a
stimulated release event itself is expected to occur within seconds20, it well established that
extracellular ATP concentrations can remain elevated for several minutes, particularly under static
bath conditions60-67. Similar to these previous reports, we observed that ecAT3.10 detected a
suramin-sensitive increase in extracellular ATP following ADP treatment. Under these static bath
conditions the increases occurred and persisted over several minutes, which is not attributed solely
to the intrinsic kinetics of the sensor because the sensor itself can respond to changes in
extracellular ATP levels within seconds. Instead, the persistant elevation in ATP likely reflect
recurrent activation and release, which has been previously hypothesized85. Interestingly, despite
its apparent affinity, Kapp = 12 µM ATP, the sensor showed a strong response to stimulated release.
Because the surface-tethered sensor does not require a diffusible substrate, the response correlates
to the actual ATP dynamics at the cell surface. Hence, our observations suggests that surface ATP
levels may indeed reach higher peak ATP concentrations than previously estimated. It will be
interesting to use ecAT3.10 to study ATP release in vivo in the future because the extracellular
volume constraints in intact tissue, in addition to differences between surface and bulk dynamics,
are fundamental to the spatial and temporal components of purinergic signaling.
In summary, ecAT3.10 is a genetically-encoded and ratiometric fluorescent sensor of
extracellular ATP that represents an important first-step in the creation of a new set of tools
available for studying purinergic signaling in live specimens with single-cell resolution.
Fluorescent protein-based sensors have emerged as powerful molecular tools to quantitatively
visualize analyte dynamics in real-time, with subcellular resolution, and with the potential for cellspecific expression in vitro and in vivo. The ecAT3.10 is a CFP-YFP based sensor that is
compatible with red fluorescent sensors, for example such as the calcium sensors86-90 and pH
sensors91, that can be multiplexed to study signal transduction or improve quantitative calibration.
Furthermore, the current work suggests that other available soluble ATP sensors can potentially
be re-engineered as surface tethered sensors of extracellular ATP, though the current work also
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demonstrates the need for live-cell characterization. One of the potential challenges that calls for
a broad toolset of sensors is the large concentration range of extracellular ATP in basal and
stimulated conditions. For this reason, it will be important to engineer both ratiometric sensors92
to study changes occurring over slower timescales as well as intensiometric sensors93 to study
faster events. By optimizing dynamic range, affinity ranges, and surface tether length, these
sensors will ultimately enable purinergic researchers to study compartmentation of ATP dynamics
in vivo in the future.

1.4
1.4.1

Methods
Materials
Standard chemicals and cell culture reagents were purchased from Sigma and

ThermoFisher. ARL67156, suramin, and PPADS were purchased from Tocris.

1.4.2

Data Collection and Analysis
J.M.C. and M.T. designed all experiments. J.M.C, S.R., S.A.V., and M.T. carried out

experiments and analyzed data (Table S1). J.M.C. carried out experiments, and J.M.C. and M.T.
analyzed data presented in Figs 1, 2, 5, and associated Supplemental Figures. J.M.C carried out
experiments independently from S.R. and S.A.V., and all authors analyzed data for Figs 3, 6, 7,
and associated Supplemental Figs. S.R. and S.A.V. carried out experiments, and S.R., S.A.V., and
M.T. analyzed data in Fig 4 and associated Supplemental Figs. S.R. and S.A.V. contributed
equally to this work. J.M.C. and M.T. wrote the manuscript, and all authors edited the manuscript.
Unpaired, two-tailed Student’s t-test was used to test for differences in means. Mean values
are reported with standard errors of the mean (mean ± sem).

1.4.3

Sensor Construction
ecAT3.10.

The pCMV(MinDis).iGluSnFR plasmid (Addgene plasmid #41732), a

modified version of the pDisplay vector that has the hemagglutinin (HA) tag removed and contains
the iGluSnFR glutamate sensor, was used as a template for construction of the ecATeam sensors.
The plasmid was restriction enzyme digested with BglII and SalI for removal of iGluSnFR
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sequence, but retention of the coding region for the IgΚ leader sequence and PDGFR
transmembrane domain.

The ATeam3.10 insert was prepared, as follows.

The pRSetB-

ATeam3.10 vector (from H. Imamura) was restriction enzyme digested with XbaI and EcoRI to
divide the ATeam3.10 sequence into 2 fragments that separate the homologous cyan and yellow
fluorescent protein sequences to allow for specific PCR amplification. Subsequently, the Nterminal

ATeam3.10

fragment

was

amplified

with

the

and

CAGGTTCCACTGGTGACAGAATGGTGAGCAAGGGCG–3’

5’5’–

CACCATGAATTCCTTCATTTCGGCAACG–3’ oligonucleotide primer pair and the C-terminal
fragment was amplified with the 5’–GAAATGAAGGAATTCATGGTGAGCAAGGGC–3’ and
5’–GATGAGTTTTTGTTCGTCGACCTTGTACAGCTCGTCCATGC–3’
primer pair using Phusion polymerase (Fisher Scientific).

oligonucleotide

Upon gel purification, the

pCMV(MinDis) vector fragment and the two PCR-amplified ATeam3.10 fragments were used for
a 3-fragment Gibson Assembly reaction (NEBuilder Gibson Assembly, New England Biolabs)
that yielded the pCMV(MinDis)-ATeam3.10 construct (ecAT3.10).
ecAT1.03-YEMK. The pCMV(MinDis).iGluSnFR plasmid was also used as a template
for

construction

of

the

ecAT1.03-YEMK

construct.

Here,

CCGCCACAACATCGAGTACCTGCAGGTTGACGAACAAAAACTCATCTC-3’

and

5’5’-

TTGCTCACCATACTCGAGTAGTCACCAGTGGAACCTG-3’ oligonucleotide primers were
used with Phusion polymerase to PCR amplify a fragment of the pCMV(MinDis).iGluSnFR
plasmid that retains the IgΚ leader sequence and PDGFR transmembrane domain, but is devoid of
the iGluSnFR sequence.

The insert fragment containing AT1.03-YEMK was prepared by

restriction enzyme digest of pcDNA-AT1.03(YEMK) (from H. Imamura) with XbaI and HindIII.
The final pCMV(MinDis)-AT1.03-YEMK (ecAT1.03-YEMK) construct was generated by Gibson
Assembly (NEBuilder, New England Biolabs) of the insert fragment with the PCR amplified
pCMV(MinDis) vector fragment.
Upon preparation of plasmid DNA, all coding sequences of the final ecATeam constructs
were confirmed by Sanger sequencing at Genewiz (South Plainfield, NJ).

1.4.4

Cell Line Maintenance and Transfection
N2A cells (ATCC CCL-131), HEK293 cells (ATCC CRL-1573), and SK-MEL-5 (ATCC

HTB-70) were cultured in Dulbecco’s modified Eagle’s medium containing 4.5 g/L glucose, 2
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mM glutamine, and supplemented with 10% cosmic calf serum or 10% fetal bovine serum and
were maintained at 37°C and 5% CO2 in a humidified incubator. N2A cells were confirmed to be
mycoplasma free as assessed by the Universal Mycoplasma Testing Kit (ATCC). For imaging
experiments, cells were seeded, as indicated, onto nitric acid-cleaned and washed 18-mm #1.5
coverslips, or into Cellvis 12-well or 24-well glass bottom plates with high performance #1.5 cover
glass that were cleaned with NaOH/H2O2, washed, and pre-coated with poly-D-lysine. Cells were
then transfected with plasmid DNA for expression of ecATeam sensors by living cells using the
Effectene (Qiagen) transfection reagent as described in the manufacturer’s protocol.

1.4.5

Live-Cell Fluorescence Microscopy and Image Analysis
Cells were prepared for microscopy by exchanging cell growth media for imaging solution

consisting of 15 mM HEPES, 1.25 mM NaH2PO4, 10 mM glucose, 120 mM NaCl, 3 mM KCl, 2
mM CaCl2, 1 mM MgCl2, and 3 mM NaHCO3 (pH 7.3) and cells were equilibrated at room
temperature for at least 20 min prior to imaging. All microscopy experiments were performed at
ambient room temperature, either during continuous perfusion (~1.5 mL/min flow rate) of imaging
solution (or indicated treatment), or in the presence of a static bath of imaging solution where
treatments were added by pipette to the bulk solution of the static bath. Cells were imaged using
an Olympus IX83 fluorescence microscope with a 20X/0.75 NA objective illuminated by a
Lumencor SpectraX light engine and equipped with an Andor Zyla 4.2 sCMOS camera. The
ecATeam sensor activity was measured by examining the fluorescence intensities in CFP, CFPYFP FRET, and YFP channels. Specifically, the ATeams were excited in the CFP and CFP-YFP
FRET channels using a 438/29 nm bandpass filter, and emission was collected through 470/24 and
540/30 nm bandpass filters for the CFP and CFP-YFP FRET channels, respectively.

The

fluorescence in the YFP channel was excited using a 510/10 nm bandpass filter and emission was
collected through a 540/30 nm bandpass filter. Excitation light from all fluorescence channel
measurements was blocked by the ET-ECFP/EYFP/mCherry multiband beamsplitter (Chroma
69008bs). The microscope components and image acquisition were controlled by the Andor iQ3
software and the ImageJ/FIJI software package was used to analyze all images for each experiment,
as specified. For fluorescence images, the mean and standard deviation of background intensities
were measured for each fluorescence channel in every field of view. For each fluorescence channel,
the mean background intensity was subtracted from every image of the associated imaging set.
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Background masks were then created with minimum thresholds of two times the mean background
intensity.

The background masks were applied to the fluorescence intensity images and

fluorescence ratio images were created by pixel-by-pixel division of the background masked
individual fluorescence channels. Regions of interest that encompassed whole cells or cell
membranes, as indicated, were drawn and the mean fluorescence ratios of pixels within each region
of interest were calculated.
For kinetic measurements, experiments were performed at ambient room temperature using
a diamond-shaped laminar flow fast perfusion chamber (Warner RC-25F). Imaging solution was
perfused at a rate of 5 mL/min, and inhibitors were not used. Images were collected at 2 second
intervals for the FRET and YFP fluorescence emission channels. Data was fit to a two-exponential
association function,y = y0 + A1·(1-e(-t/τ1) + A2·(1-e(-t/τ2)).
Confocal microscopy was carried out on a Nikon A1 confocal system with a Ti-E
microscope base, using a 60X/1.49 NA Nikon apo TIRF objective at room temperature. The 457
nm line of a mult-argon laser was used for excitation, and CFP and FRET channel fluorescence
intensities were collected using 482/35 nm and 525/50 nm bandpass filters.

1.4.6

Luciferase Assay
Neuro2A cells were maintained, seeded onto nitric acid-cleaned 18-mm #1.5 glass

coverslips, transfected, and prepared as described for live-cell fluorescence microscopy
experiments in imaging solution. Cells were imaged for ecAT3.10 fluorescence in a coverslip
chamber under static bath conditions, without solution exchange. While imaging ecAT3.10 in
Neuro2A cells, 25 μl of extracellular imaging solution was removed at various time points and
immediately frozen and stored at -80°C until assay. The ATP concentrations in the extracellular
imaging solution aliquots were measured using a commercial luminescence ATP detection assay
system (ATPlite, PerkinElmer) and quantified compared to an ATP standard curve.

1.4.7

Ateam3.10 Expression and Purification
E. coli strain BL-21 expressing pRSetB-ATeam3.10 was cultured in Auto Induction Media

(AIM) at 37 °C for 12h then at room temp for 36h. Cells were then pelleted, resuspended in lysis
buffer (25 mM Sodium Phosphate Buffer [pH 7.8], 500 mM NaCl, 10 mM Imidazole, 5% Glycerol,
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0.1% Triton X-100, 1mM PMSF, 1mM DTT, and 0.2 mg/mL Lysozyme), and lysed by sonication.
Lysate was then centrifuged at 30,000xg for 30min at 4°C, and passed through a 0.45 μm syringe.
The sample was then run over a Ni column (GE Chelating Sepharose column charged with Ni2+).
The column was then washed with wash buffer A (25 mM Sodium Phosphate Buffer [pH 7.8], 500
mM NaCl, 20 mM Imidazole, 5% Glycerol), wash buffer B (25 mM Sodium Phosphate Buffer
[pH 7.8], 500 mM NaCl, 40 mM Imidazole, 5% Glycerol), then elution buffer (25 mM Sodium
Phosphate Buffer [pH 7.8], 500 mM NaCl, 150 mM Imidazole, 5% Glycerol). The fractions
containing purified ATeam 3.10 were dialyzed in storage buffer (5 mM MOPS Buffer [pH 7.3],
300 mM NaCl, 10% Glycerol), with two changes at 4°C and stored at -80 °C for future use.

1.4.8

Purified AT3.10 in vitro Spectroscopy
Protein concentration was determined using a standard procedure micro Bradford Assay

(Thermo Scientific). The protein was diluted to 0.125 μM in assay buffer (50 mM MOPS-KOH,
pH 7.3, 50 mM KCl, 0.5 mM MgCl2, and 0.05% Triton X-100) and fluorescence was measured
using a BioTek Synergy H4 microplate reader at room temperature, in the absence and presence
of ATP, ADP, ARL67156, PPADS, or Suramin. For all filter based measurements, a 420/50 nm
excitation and 485/20 and 528/20 nm emission filters were used
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GENETICALLY-ENCODED, RATIOMETRIC
FLUORESCENT SENSOR WITH NANOMOLAR AFFINITY

2.1

Introduction
ATeam, a genetically encoded biosensor used to detect ATP, is composed of the CFP and

mVenus FRET pair connected by the epsilon subunit of ATP synthase. Several variants of ATeam
have been developed to measure a range of concentrations from micromolar to millimolar levels,
using the ε subunit from Bacillus sp. PS3 in ATeam3.10 and the ε subunit from Bacillus subtilis
in ATeam1.03, respectively. However, despite the range covered, there is still a need to create a
higher affinity sensor to more accurately detect and measure extracellular ATP and to shift the
affinity range to better span the stimulated release window (10-3-10-8 M). Kato-Yamada et al95,96
recently demonstrated that the R103A/R115A mutation of the Bacillus sp. PS3 epsilon subunit
increases ATP affinity by two orders of magnitude. In this paper, we have investigated these
charge-neutralizing arginine-to-alanine mutations applied to the ATeam family of sensors, as well
as charge-reversal arginine-to-glutamate mutations, and we identified new sensors capable of
detecting changes in ATP at nanomolar concentrations.

2.2

2.2.1

Results and Discussion

ATeam3.10 Mutations Increase ATP Affinity
To increase the affinity of the epsilon subunit of ATeam3.10, we generated eight mutants

at the R103 and R115 positions based on the observations by Kato-Yamada95,96, creating a small
combinatorial library of single and double R-to-A and R-to-E mutants. ATP dose-responses of
purified soluble ATeam3.10 WT and mutants showed a threefold increase for the R103A/R115A
(Kapp = 0.245μM) and R103A/R103E (Kapp =0.197 μM) mutants when compared to WT (Kapp
=0.774 μM) at room temperature (Fig 2.2 and Table 2.1). A single-site binding model was used to
fit dose-response curves and account for ligand depletion at the sensor concentration used in the
assay (0.250 M). This trend was expected, although the increase in affinity of the mutants were
not as high as the two orders of magnitude reported in the epsilon subunit without two fluorescent
proteins. Interestingly, while the R103A and R115A single mutants had little effect on the apparent
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affinity, the R115E single mutant showed a two fold increase (Kapp =0.352μM) (Fig 2.2 and Table
2.2).

Figure 2.1. Crystal Structure of Bacillus sp. PS3
Residues of interest (R103, R115) as well as the residues interacting with the ATP substrate are
indicated.
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Figure 2.2. Dose response curves for the wild type and mutants generated from the three variants
of ATeam.
High affinity ATeam 3.10 is on the left, blue line is WT, red lines is R103A/R115A mutant, orange
line is R103A/R115E mutant. Low affinity variants on the right, ATeam1.03 are the grey lines and
ATeam1.03-YEMK are the orange lines.

Table 2.1. Average Kapp for all ATeam3.10 single mutants dose responses shown in Fig 2.2 n=4
experiments

AT3.10
R103A
R103E
R115A
R115E

ATP Binding for a Single-Site Binding Model
Kapp (Molar)
Mean
Std. Dev.
Std. Error
95% CI
8.56E-07
3.41867E-07 8.76E-08 3.35E-07
8.57E-07
3.68963E-07 1.69E-08 3.616E-07
5.70E-07
3.48286E-07 1.35E-08 3.413E-07
6.10E-07
2.60028E-07 7.11E-09 2.548E-07
3.52E-07
9.73803E-08 6.04E-09 9.543E-08
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Table 2.2. Average Kapp for all ATeam3.10 double mutants dose responses shown in Fig 2.2 n=4
experiments

AT3.10
R103A/R115A
R103A/R115E
R103E/R115A
R103E/R115E

2.2.2

ATP Binding for a Single-Site Binding Model
Kapp (Molar)
Mean
Std. Dev.
Std. Error 95% CI
7.74E-07
2.99294E-07 7.90E-08 2.93E-07
2.45E-07
1.31915E-07 7.85E-09 1.29E-07
1.97E-07
1.05848E-07 9.59E-09 1.04E-07
6.95E-07
3.12687E-07 1.36E-08 3.06E-07
7.75E-07
3.58591E-07 2.14E-08 3.51E-07

ATeam1.03 Mutations Decrease ATP Affinity
We next attempted to create a sensor that has an apparent affinity that is more fully in the

stimulated release window (10-3-10-8 M) by mutating the ATeam1.03 and ATeam1.03-YEMK
variants, which both use the ε subunit from Bacillus subtilis. Upon further investigation, the
mutations in both constructs caused an opposite effect on ATP binding and in some cases, such as
ATeam1.03-YEMK-R103A, the mutations cause a complete loss of ATP binding (Tables 2.3- 2.6).
Interestingly further mutation of the same construct to generate the ATeam1.03-YEMKR103A/R115E mutant partially restores apparent affinity to 1.94 mM (Table 2.6). After several
attempts at purification, ATeam1.03-YEMK-103E continuously underwent cleavage, losing the
YFP, and therefore it was not further characterized.

Table 2.3. Average Kapp for all ATeam1.03 single mutants dose responses shown in Fig 2.2 n=4
experiments
ATP Binding for Hill Equation Fitting
Kapp (Molar)
Std.
Mean
Std. Dev. Error
95% CI
AT1.03
1.54E-03 0.000125 2.15E-05 0.000123
103A
1.48E-02 0.008894 1.18E-02 0.008715
103E
1.07E+37 2.15E+37 1.78E+01 2.11E+37
115A
8.89E-03
0.00425 7.04E-03 0.004165
115E
5.18E-03 0.001042 1.22E-03 0.001021
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Table 2.4. Average Kapp for all ATeam1.03 double mutants dose responses shown in Fig 2.2 n=4
experiments
ATP Binding for Hill Equation Fitting
Kapp (Molar)
Mean
Mean
Mean
Mean
AT1.03
5.39E-04 4.53768E-05 1.63E-05 4.44685E-05
R103A/R115A
3.37E-03 0.000949667 8.50E-01 0.000931656
R103A/R115E
3.28E-03 0.000773579 5.90E-04 0.000758094
R103E/R115A
2.38E-03 0.001445636 7.94E-04 0.001416698
R103E/R115E
3.73E-03 0.000919397 1.98E-03 0.000900993

Table 2.5. Average Kapp for all ATeam1.03-YEMK single mutants dose responses shown in Fig
2.2 n=4 experiments

AT-YEMK
103A
103E
115A
115E

ATP Binding for Hill Equation Fitting
Kapp (Molar)
Mean
Mean
Mean
Mean
2.17E-04 1.14E-05 1.14E-05 1.11E-05
3.12E-01 2.50E+00 2.50E+00 2.448546
9.38E-03 9.83E+16 4.91E+16 9.63E+16
1.82E-03 1.42E-04 1.35E-04 0.000139
6.94E-04 2.43E-05 1.65E-05 2.39E-05

Table 2.6. Average Kapp for all ATeam1.03-YEMK double mutants dose responses shown in Fig
2.2 n=4 experiments
ATP Binding for Hill Equation Fitting
Kapp (Molar)
Mean
Mean
Mean
Mean
AT-YEMK
1.32E-04
2.4577E-05 9.59E-06 2.41E-05
R103A/R115A
1.36E-02 0.013895919 1.13E-02 0.013618
R103A/R115E
1.94E-03 0.000234023 5.53E-05 0.000229
R103E/R115A
1.93E-03 0.000176635 6.24E-05 0.000173
R103E/R115E
2.17E-03 0.00029149 1.33E-04 0.000286
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2.2.3

Mutations Alter ADP and AMP Affinity
Whenever mutations are made that affect the affinity of a sensor for its substrate, structural

analogs should be tested. In the previous chapter, ATeam3.10 has shown a millimolar affinity for
ADP, so we tested ADP and AMP at 100 µM and 1 mM in comparison to vehicle and high ATP.
All ATeam3.10 mutants show an increase in affinity for AMP and most show an increase in ADP
affinity, however ATeam 3.10-R103A/R115A and R103A/R115E show an nearly maximal FRET
Ratio for ADP at 100 µM (Fig 2.3, 2.4). The ATeam1.03-YEMK and ATeam1.03 mutants all show
no response from either ADP or AMP and most do not respond to ATP, confirming the loss of
affinity.

2.5
2

FRET Ratio

0
AMP 0.0001

1.5

AMP 0.001
ADP 0.0001

1

ADP 0.001
0.5

ATP 0.0001

0
AT3.10

R103A

R103E

R115A

R115E

Figure 2.3. Response of ATeam3.10 single mutants to AMP and ADP
The FRET ratio response for each construct was recorded for vehicle, 100µM AMP, 1 mM AMP,
100µM ADP, 1 mM ADP, and 100µM ATP. n= 2 experiments
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FRET Ratio

2
1.5

0
AMP 0.0001

1
0.5

AMP 0.001
ADP 0.0001
ADP 0.001

0

ATP 0.0001

Figure 2.4. Response of ATeam3.10 double mutants to AMP and ADP
The FRET ratio response for each construct was recorded for vehicle, 100µM AMP, 1 mM AMP,
100µM ADP, 1 mM ADP, and 100µM ATP. n= 2 experiments

2.5

FRET Ratio

2
1.5
1

0
AMP 0.0001
AMP 0.001
ADP 0.0001

0.5

ADP 0.001
ATP 0.0001

0

Figure 2.5. Response of ATeam1.03-YEMK mutants to AMP and ADP
The FRET ratio response for each construct was recorded for vehicle, 100µM AMP, 1 mM AMP,
100µM ADP, 1 mM ADP, and 100µM ATP. n= 2 experiments
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2.3
2.3.1

Methods
Materials
Standard chemicals and cell culture reagents were purchased from Sigma and

ThermoFisher.

2.3.2

Mutant Sensor Construction
pRSetB-ATeam3.10, pRSetB-ATeam1.03, and pRSetB-ATeam1.03-YEMK mutants. The

pRSetB-ATeam3.10 (from H. Imamura), pRSetB-ATeam1.03, pRSetB-ATeam1.03-YEMK
vectors were used as templates. The mutants were generated using the primers listed in the table
below and the standard protocol using NEB Q5 site-directed mutagenesis kit. Upon preparation
of plasmid DNA, all coding sequences of the final mutant ATeam constructs were confirmed by
Sanger sequencing at Genewiz (South Plainfield, NJ).

Table 2.7. List of primers used to generate mutant ATeam constructs
pRset-AT1.03
and pRset-AT1.03YEMK
nt0819_B.subtilis_eps_R103A_F
nt0820_B.subtilis_eps_R103A-E_R
nt0821_B.subtilis_eps_R103E_F
nt0822_B.subtilis_eps_R115A_F
nt0823_B.subtilis_eps_R115A-E_R
nt0824_B.subtilis_eps_R115E_F

Sequence
GGCCCAGGAGGCCCTGAACTCTCAATC
CTCTGTCTTGCGGCTTCT
GGCCCAGGAGGAGCTGAACTCTC
CGATATTCGCGCTGCCGAGCTGG
GTGTCATCGGATTGAGAG
CGATATTCGCGAGGCCGAGCTG

pRset-AT3.10
nt0693_BsPS3epsilon_R103A_F
nt0694_BsPS3epsilon_R103A-E_R
nt0695_BsPS3epsilon_R103E_F
nt0696_BsPS3epsilon_R115A_F
nt0697_BsPS3epsilon_R115A-E_R
nt0698_BsPS3epsilon_R115E_F

Sequence
GGCGGAGCGCGCCCTGCAAAGCC
CGCTCTTTCGCCGCTTTG
GGCGGAGCGCGAGCTGCAAAGCC
CGACTTCAAAGCAGCCGAACTGGCGTTAAAAC
ATGTCGTCCTGCTGGCTT
CGACTTCAAAGAGGCCGAACTGGCG
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2.3.3

ATeam3.10 Expression and Purification
E. coli strain BL-21 expressing pRSetB-ATeam3.10 was cultured in Auto Induction Media

(AIM) at 37 °C for 12h then at room temp for 36h. Cells were then pelleted, resuspended in lysis
buffer (25 mM Sodium Phosphate Buffer [pH 7.8], 500 mM NaCl, 10 mM Imidazole, 5% Glycerol,
0.1% Triton X-100, 1mM PMSF, 1mM DTT, and 0.2 mg/mL Lysozyme), and lysed by sonication.
Lysate was then centrifuged at 30,000xg for 30min at 4°C, and passed through a 0.45 μm syringe.
The sample was then run over a Ni column (GE Chelating Sepharose column charged with Ni2+).
The column was then washed with wash buffer A (25 mM Sodium Phosphate Buffer [pH 7.8], 500
mM NaCl, 20 mM Imidazole, 5% Glycerol), wash buffer B (25 mM Sodium Phosphate Buffer
[pH 7.8], 500 mM NaCl, 40 mM Imidazole, 5% Glycerol), then elution buffer (25 mM Sodium
Phosphate Buffer [pH 7.8], 500 mM NaCl, 150 mM Imidazole, 5% Glycerol). The fractions
containing purified ATeam 3.10 were dialyzed in storage buffer (5 mM MOPS Buffer [pH 7.3],
300 mM NaCl, 10% Glycerol), with two changes at 4°C and stored at -80 °C for future use.

2.3.4

Expression of Various ATeam Constructs and Mutants
E. coli strain BL‐21 expressing the sensor was cultured in Auto Induction Media (AIM) at

37 °C for 12h then at room temp for 36h. Cells were then pelleted, resuspended in lysis buffer (25
mM Sodium Phosphate Buffer [pH 7.8], 500 mM NaCl, 10 mM Imidazole, 5% Glycerol, 0.1%
Triton X‐100, 1mM PMSF, 1mM DTT, and 0.2 mg/mL Lysozyme), and lysed by sonication.
Lysate was then centrifuged at 30,000xg for 30min at 4°C, and passed through a 0.45 μm syringe.
The sample was then purified using an AKTAprime plus chromatography system and a Ni column
(GE Chelating Sepharose column charged with Ni2+). The column was then washed with 10
volumes of wash buffer (25 mM Sodium Phosphate Buffer [pH 7.8], 500 mM NaCl, 10 mM
Imidazole, 5% Glycerol) and then elution buffer (25 mM Sodium Phosphate Buffer [pH 7.8], 500
mM NaCl, 500 mM Imidazole, 5% Glycerol) with 30 volumes, using an increasing imidazole
gradient. The fractions containing purified ATeam 3.10 were dialyzed in storage buffer (5 mM
MOPS Buffer [pH 7.3], 300 mM NaCl, 10% Glycerol), and stored at ‐80 °C for future use.
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2.3.5

Purified AT3.10 in vitro Spectroscopy
Protein concentration was determined using Beer’s Law and chromophore denaturation in

1M NaOH, wavelength: 448nm, ε=44000 L*mol-1*cm-1. The protein was diluted to 0.125 μM in
assay buffer (50 mM MOPS‐KOH, pH 7.3, 50 mM KCl, 0.5 mM MgCl2, and 0.05% Triton X‐
100) and fluorescence was measured using a BioTek Synergy H4 microplate reader at room
temperature, in the absence and presence of ATP, ADP, or AMP. For all filter based measurements,
a 420/50 nm excitation and 485/20 and 528/20 nm emission filters were used.

2.4

Conclusion:

Future Work

We have increased the affinity of ATeam3.10 threefold to ~200 nM by applying the
R103A/R115A mutations to the epsilon subunit. This increase in ATP affinity is very promising,
however further mutations in the region may be investigated to further increase the affinity. Work
has already begun on the application of these mutations to the ecATeam sensor from chapter 1. In
addition to the increase in ATP, the mutations have also affected the affinity of the sensor for ADP
and AMP. This has both positive and negative consequences because further work must be done
to increase the specificity of the sensor. However, this is promising because there is a need for a
genetically encoded AMP sensor and these mutations may open a whole new window to create a
sensor, possibly by sterically blocking the beta and gamma phosphates.
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